Pareptide monohydrochloride

Cat. No.: HY-U00271: Fiche technique Instruction de manipulation
FAQs
Technical Support

Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pareptide monohydrochloride Chemical Structure

CAS No. : 63236-23-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Obtenir un devis
100 mg		Obtenir un devis
250 mg		Obtenir un devis
Other size		Obtenir un devis

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Recommandations en vedette

•Related Small Molecules:

•Related Proteins:

Voir tous les produits spécifiques à Isoform Melatonin Receptor:

Voir toutes les isoformes

MT1 MT2

Activité biologique
Protocole
Pureté et documentation
Références
Avis client

Description	Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.
In Vivo	Chronic coadministration of Pareptide (0.25 mg/kg, SC, BID, 3.5 days) to mice pretreated with Haloperidol (8.0 mg/kg, IP, BID, 3 days) significantly increases the cataleptic effects of a smaller challenge dose of Haloperidol (2.0 mg/kg, IP) given 15 hours after the last pretreatment injections (p<0.01)^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Masse moléculaire	334.84
Formule	C₁₄H₂₇ClN₄O₃
CAS No.	63236-23-7
SMILES	O=C([C@@H]1CCCN1)N(C)[C@H](CC(C)C)C(NCC(N)=O)=O.Cl
Livraison	Room temperature in continental US; may vary elsewhere.
Stockage	Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation	Fiche technique (268 KB) Instruction de manipulation (2659 KB)
Références	[1]. Mycroft FJ, et al. Pro-Leu-Gly-NH2 and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7. [Content Brief]

Administration animale
^[1]

Mice^[1]
Male albino mice of a Swiss-Webster derived strain and eighing from 26-34 g are used. Single doses of MIF-I (0.03-2.0 mg/kg, SC) and chronic pretreatments with MIF-I (0,03-2.0 mg/kg, SC, BID, 3.5 days) or Pareptide (0.25 mg/kg, SC, BID, 3.5 days) do not affect the acute cataleptic response to Haloperidol in the mouse. Pareptide is given SC in a 5 mL/kg injection volume. Chronic pretreatment with Haloperidol (8.0 mg/kg, IP, BID, 3 days) decreases the duration of catalepsy in mice given smaller challenge doses of Haloperidol (2.0 or 3.0 mg/kg, IP) 15 hours after the last pretreatment injections. Administration of either MIF-I or Pareptide to mice also chronically pretreated with Haloperidol antagonizes the development of tolerance^[1].

MCE n'a pas confirmé de manière indépendante l'exactitude de ces méthodes. Ils sont pour référence seulement.

Références

[1]. Mycroft FJ, et al. Pro-Leu-Gly-NH2 and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7. [Content Brief]